REG - Dechra Pharmaceutcls - Director/PDMR Shareholding

Dechra PharmaceuticalsAnnouncement

05/04/2022 16:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220405:nRSE3712Ha&default-theme=true

RNS Number : 3712H  Dechra Pharmaceuticals PLC  05 April 2022

 

 

 

5 April 2022

 

Dechra Pharmaceuticals PLC

(the Company)

Notification of Transactions by Person Discharging Managerial Responsibilities

 

Dechra Pharmaceuticals PLC has been notified that on 5 April 2022 Alison
Platt, Non-Executive Chair, purchased 2,346 ordinary shares in the Company.

 

Following this acquisition, Alison Platt's beneficial interest in the Company
is 3,709 shares (0.003% of the current issued share capital).

 

The Notification of Dealing Form set out below is provided in accordance with
the requirements of the UK Market Abuse Regulation.

 

Notification of Dealing Form

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")/person
     closely associated with them ("PCA")
 a)  Name                                     Alison Platt

 2.  Reason for the notification
 a)  Position/status                          Director

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Dechra Pharmaceuticals PLC
 b)  LEI code                                 213800J4UVB5OWG8VX82
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 1 pence each

     Identification code

                                              ISIN: GB0009633180
 b)  Nature of the transaction                Purchase of Shares
 c)  Price(s) and volumes(s)                  Price(s)                    Volume(s)

                                              £42.298                     2,346
 d)  Aggregated information

     -  Aggregate volume                      2,346

     -    Price                               £42.298

     -    Total                               £99,231.11
 e)  Date of the transaction                  5 April 2022
 f)  Place of the transaction                 London Stock Exchange

 

 

 

For further information, please contact:

 

Melanie Hall, Company
Secretary

Telephone number: 01606 814730

 

 

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products
business.  Our expertise is in the development, manufacture, and sales and
marketing of high quality products exclusively for veterinarians worldwide.
Dechra's business is unique as the majority of its products are used to treat
medical conditions for which there is no other effective solution or have a
clinical or dosing advantage over competitor products.  For more information
please visit: www.dechra.com

 

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra
Pharmaceuticals PLC.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBUGDSXBGDGDU